Authors
Loading...
In silico research reveals C-64 as a potent VEGFR-2 inhibitor, suggesting improvements in cancer therapy.
Wanode et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: